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Edited by Lukas HuberAbstract BH3-only proteins are required for execution of
apoptotic cell death. We have found that one of these proteins,
Bik, is strongly induced in cancer cells treated with chemothera-
peutic agents. Furthermore, we showed that chemotherapy-in-
duced expression of bik is independent of p53. Consistent with
its pro-apoptotic activity, blockade of bik expression reduces
the adriamycin-mediated apoptotic cell death. We also found
that the bik gene is transcriptionally activated by E2F proteins.
Consistently, adriamycin induces the E2F-bik pathway. In addi-
tion, E2Fs transactivate bik by a p53-independent mechanism.
Thus, our data indicate that transcriptional regulation of bik
contributes to the eﬃcient apoptotic response to chemotherapeu-
tic agents.
 2006 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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BH3-only proteins serve as upstream sentinels that selec-
tively respond to apoptotic stimuli inducing activation of other
members, mainly Bax and Bak, required for execution of cell
death [1]. All BH3-only proteins can bind to pro-survival
Bcl-2-like proteins. Blockade of expression or activation of dif-
ferent BH3-only proteins has been associated with cancer cell
survival. To this end, it has been shown that mice deﬁcient
in Bad progress, with aging, to diﬀuse large B cell lymphoma
[2]. Additionally, Hrk is methylated in colorectal and gastric
cancer cell lines, which correlates with loss of expression of this
proapoptotic gene. Blockade of other BH3-only genes such as
Noxa or Bim promotes resistance to chemotherapeutic agents
in diﬀerent tumour cell models [3,4].
A number of transcription factors (p53, FoxO3a, and E2F1
among others) have been shown to promote the expression of
diﬀerent BH3-only genes, including bnip3L, hrk, bim, puma
and noxa [5,6]. Most of these transcriptional pathways are
activated in response to chemotherapeutic agents.Abbreviations: EMSA, electrophoretic mobility shift assay; ChIP,
chromatin immunoprecipitation; siRNA, small interfering RNA;
GFP, green ﬂuorescent protein
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doi:10.1016/j.febslet.2006.08.088E2F transcription factors regulate the expression of many
genes involved in diﬀerentiation, development, proliferation,
and apoptosis [7]. Although the pathway to cell cycle progres-
sion seems straightforward with a number of growth-promot-
ing E2F target genes having been described, the pathways to
apoptosis are less well deﬁned and more complex [8].
We report here a transcriptional mechanism, mediated by
E2F proteins, that promotes the expression of bik. Chemother-
apeutic agents enhance the activation of the E2F-bik pathway,
which contributes to the apoptotic response of cancer cells to
chemotherapy.2. Materials and methods
2.1. Cell culture
SHSY-5Y, NTERA-2 and HEK293T cells were maintained in
Dulbecco’s modiﬁed Eagle’s medium (DMEM) (Invitrogen, Carlsbad,
CA) supplemented with 10% fetal calf serum (Flow Laboratories,
Irvine, CA). HCT116 cells and their p53 (/) derivatives [9], a gift
from B. Vogelstein, were grown in McCoy’s 5A medium (Invitrogen)
supplemented with 10% fetal calf serum. SUM159 was incubated as de-
scribed [6]. Adriamycin and cisplatin were used at the indicated con-
centrations (Sigma, St. Louis, MO).
2.2. Analysis of apoptosis
Apoptosis was routinely determined by both an enzyme-immuno-
assay method that quantiﬁes the histone-associated DNA fragments
present in the cytosol (Roche, Mannheim, Germany) as described pre-
viously [10], and a ﬂow cytometry analysis using a phycoerythrin-
labeled annexin V antibody (Becton Dickinson, Madrid, Spain).
Values obtained with the immunoassay method were represented as
the percentage of apoptosis in comparison with a positive internal con-
trol included in each experiment.
2.3. Electrophoretic mobility shift assay (EMSA)
Nuclear extracts (5–10 lg of total protein) were incubated with a
32p-labeled double stranded DNA probe from the promoter region
of the bik gene containing the E2F site (5 0-CGAGCGCGGAATCC-
3 0). Samples were run on a 5% non-denaturing polyacrylamide gel in
200 mM Tris–borate, 2 mM EDTA. Supershifts were performed using
rabbit anti-HA or anti-Flag antibodies (Santa Cruz Biotechnology,
Santa Cruz, CA).2.4. Chromatin immunoprecipitation assay (ChIP)
Puriﬁcation of sonicated nuclear lysates and immunoprecipitation
were performed as described elsewhere [11]. Precipitates were heated
at 65 C for at least 4 h to reverse the formaldehyde cross-linking. Pro-
teins were digested in the presence of 20 lg/ll Proteinase K, and then
DNA fragments were puriﬁed with a QIAquick Spin Kit (Qiagen,
Valencia, CA). For PCR, 2 ll from a 40 ll DNA extraction and 21–
25 cycles of ampliﬁcation were used.blished by Elsevier B.V. All rights reserved.
Fig. 1. Bik is upregulated in cancer cells in response to adriamycin. (A)
Cells were treated with 1 lM adriamycin for 24 h and then, total RNA
was extracted and analyzed for the expression of BH3-only genes by
real-time quantitative PCR. Data are shown as fold induction
compared with untreated cells. All data points represent the
means ± S.D. of three independent experiments. (B) Cells were treated
with adriamycin (Adr) and at diﬀerent time points the protein levels of
Bik were determined by Western blotting. The levels of a-Tubulin were
also analyzed to assure equal loading. (C) The percentage of apoptotic
cells following treatment with adriamycin was determined by ﬂow
cytometry with FITC-labeled annexin V. Numbers above the selected
regions indicate the percentage of apoptotic cells.
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Total RNA was prepared using TRIZOL reagent (Invitrogen). To
assess mRNA expression, semiquantitative RT-PCR and quantitative
real-time PCR were performed as previously described [6,10]. The gen-
erated cDNA was ampliﬁed by using primers for human bnip3, bim,
bik, bnip3L, b-actin, [6] and puma (5 0-ACGACCTCAACGCACAG-
TACG and 5 0-TGGGTAAGGGCAGGAGTCC).
Protein expression was determined by Western blotting as described
[6]. Blots were incubated with rabbit anti-Bik, and anti-HA antibodies
(Santa Cruz Biotechnology), or mouse anti-b-Tubulin (Sigma) anti-
bodies.
2.6. Gene silencing
HCT116 cells were transfected with a pool of four small interfering
RNA (siRNA) duplexes (100 nM) speciﬁc for human bik (Dharmacon,
Chicago, IL) by using lipofectamine 2000 (Invitrogen) as recom-
mended by the manufacturer. After 24 h of transfection, 2 lM adria-
mycin was added to the culture and cells were incubated for another
24-h period. A pool of four irrelevant siRNA duplexes was also used
as a negative control.
2.7. Transfections and gene reporter assays
A genomic PCR fragment of 596 bp from the promoter region of bik
(bik-pt), was cloned into KpnI and HindIII sites of the pGL2-basic
luciferase reporter vector (Promega Corp., Madison, WI). HEK293T
cells were co-transfected with 1 lg of pGL2-bik-pt, 1 lg of E2F1,
E2F2 or E2F3 cDNAs cloned into the Flag/HA-tag containing
pcDNA3 expression vector [12], and 50 ng of pRSV-b-gal by lipofec-
tion using Superfect (Qiagen). Twenty-four hour post-transfection, cell
extracts were prepared and analyzed for the relative luciferase activity
by a dual-light reporter gene assay system (Applied Biosystems, Foster
City, CA).3. Results
3.1. Bik is induced by chemotherapeutic agents in cancer cells
through a p53-independent pathway
We searched for pro-apoptotic BH3-only genes diﬀerentially
expressed in SHSY-5Y and NTERA-2 cancer cells following
treatment with chemotherapeutic agents. Adriamycin pro-
voked about a 40-fold and 20-fold induction of bik mRNA
in SHSY-5Y and NTERA-2, respectively. The levels of puma
were also found to increase 7-fold in SHSY-5Y and 30-fold in
NTERA-2; whereas those of bim, bnip3 and bnip3L increased
(3–9-fold) only in NTERA-2 cells (Fig. 1A). Furthermore, we
observed a time-dependent induction of Bik protein after treat-
ment with adriamycin (Fig. 1B). Consistent with the cell death
promoting eﬀect of adriamycin, most SHSY-5Y cells under-
went apoptosis within 24 h of treatment (Fig. 1C).
Puma is a well known p53 target gene; however, the expres-
sion of bik has been reported to be both p53-dependent and
p53-independent. We treated p53-deﬁcient and wild type
HCT116 cells with adriamycin or cisplatin, and showed that
the mRNA levels of bik increased in response to chemotherapy
regardless of the presence of p53 (Fig. 2A). However, puma
was only upregulated in wild type cells. Furthermore, p53-deﬁ-
cient cells showed much lower levels of apoptosis than those
detected in wild type cells (Fig. 2B). To study the relevance
of bik in chemotherapy-induced apoptosis we used an RNA
interference approach that blocks bik expression. Speciﬁc siR-
NA decreased 2–3-fold the mRNA expression of bik as deter-
mined by semiquantitative (Fig. 2C) and real-time RT-PCR
(data not shown). This reduction was also conﬁrmed at the
protein level by western blot analysis (Fig. 2D), and resulted
in a 20–30% loss of the apoptotic response to adriamycin as as-
sessed by an ELISA method that quantiﬁes the histone-associ-ated DNA fragments (Fig. 2E) and by ﬂow cytometry with
annexin V (Fig. 2F).
3.2. E2F proteins transcriptionally regulate bik gene expression
We found a putative binding sequence for E2F in the bik
gene promoter, 104 bases upstream from the transcription
start site. Then, a 596 bp fragment from the promoter region,
encompassing 40 nucleotides of exon 1, was cloned into a luci-
ferase reporter vector (Bik-Luc). HEK293T is a highly eﬃcient
cell model for transient transfection experiments. Thus, we
determined the levels of luciferase activity in these cells trans-
fected with Bik-Luc in the presence of E2Fs. As shown in
Fig. 3A, all E2F proteins increased luciferase activity more
than 20-fold. To directly prove the binding of E2F proteins
to the bik promoter, HEK293T cells were transfected with
E2F-containing vectors and then nuclear extracts were sub-
jected to EMSA. As expected, in all cases we detected a pro-
tein–DNA complex (Fig. 3B). If an antibody reacted with
E2F bound to the probe, it was expected that the shifted band
either would have slower mobility (supershift) or would dis-
appear as a result of dissociation of E2F from the probe.
Fig. 3B shows that the E2F–DNA complex was removed in
the presence of antibodies against the N-terminal HA/Flag epi-
tope used as a tag. Additionally the interaction of endogenous
E2F protein with the bik promoter was demonstrated by a
ChIP assay. We observed a signiﬁcant enrichment of the pro-
moter (ampliﬁed fragment spans the region from 236 to 86)
when using the anti-E2F1 antibody (Fig. 3C). Moreover, over-
expression of E2F1 promoted an 18-fold induction of bik
mRNA levels. On the contrary, bim and puma did not show
signiﬁcant variations. Similar results were obtained with
SUM159 (Fig. 4A). In addition, treatment with adriamycin
enhanced the formation of E2F1-bik promoter binding com-
Fig. 2. Bik is induced in a p53-independent manner and contributes to the apoptotic response to chemotherapy. (A) Wild type and p53-deﬁcient
HCT116 cells were treated with 2 lM adriamycin (Adr) or 30 lM cisplatin (Cis). After 24 h of treatment, total RNA was extracted and analyzed for
the expression of bik and puma by real-time quantitative PCR. (B) Apoptotic cell death was also determined in HCT116 cells treated with increasing
concentrations of chemotherapeutic agents by an ELISA method that quantiﬁes the histone-associated DNA fragments present in the cytosol. Wild
type HCT116 cells transfected with irrelevant (control) or bik-speciﬁc siRNA duplexes were treated with 2 lM adriamycin, and after 24 h bik
expression was determined by semiquantitative RT-PCR (C), and Western blot (D) analyses, and apoptosis was analyzed by the immunoassay
method (E) and by ﬂow cytometry with FITC-labeled annexin V (F). gapdh mRNA was included as an ampliﬁcation control. All histograms
represent the means ± S.D. of three independent experiments.
Fig. 3. E2F proteins transactivate the bik promoter. (A) HEK293T
cells were transfected with Bik-Luc either in the presence or in the
absence of E2F1, E2F2 or E2F3. Following 24 h of transfection, cell
extracts were prepared and analyzed for the relative luciferase activity.
Results were normalized for transfection eﬃciency with values
obtained with pRSV-b-gal. Histograms represent the means ± S.D.
of three independent experiments. (B) Formation of E2Fs–DNA
binding complexes was determined by EMSA using a radiolabeled
probe from the bik promoter. Anti-HA and anti-Flag antibodies were
used to show the speciﬁc binding of transfected proteins. (C) A ChIP
assay was performed using SHSY-5Y cells. Cross-linked chromatin
was incubated with an antibody against E2F1 (aE1), or with an
irrelevant antibody against the T antigen (aTA). Immunoprecipitates
from each sample were analyzed by PCR using primers speciﬁc for the
bik promoter and for the gapdh coding region. As a positive control, a
sample representing 0.1% of the total input chromatin (In) was
included.
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induction of luciferase activity in cells transfected with Bik-
Luc compared with untreated cells (Fig. 4C).
3.3. p53 does not modify the E2F-dependent induction of bik
E2F proteins may induce pro-apoptotic genes by activation
of a p53-dependent transcriptional pathway. Thus, we assessed
whether E2F promoted the expression of bik through p53.
First, we co-transfected SHSY-5Y cells with Bik-Luc and
either E2F1 or p53. E2F1 promoted a signiﬁcant increase
(about 11-fold) in the levels of luciferase activity (Fig. 5A).
On the contrary, p53 did not modify the activity of the repor-
ter gene, but increased about 25-fold the luciferase activity
when a positive control promoter was used (Fig. 5A). To fur-
ther conﬁrm this, p53-deﬁcient and wild type HCT116 cells
were co-transfected with Bik-Luc and E2Fs. As shown in
Fig. 5B, luciferase activity was similarly induced in both cell
lines.
It has been described that ectopic expression of several of the
E2Fs results in apoptotic cell death [13]. We transiently
cotransfected SHSY-5Y cells with E2F1 and a green ﬂuores-
cent protein (GFP)-containing vector. After transfection, no
apoptosis was observed in the GFP-positive cell popula-
tion (Fig. 5C). To conﬁrm this result, HCT116 was transfected
with E2F1 or E2F2 (Fig. 5D). By 30 h of transfection no
evidence of apoptosis was observed as determined by an
Fig. 4. E2F proteins induce endogenous bik and activates the bik
promoter in response to adriamycin. (A) Cell lines were transfected
with E2F1, E2F2 or E2F3. Following 48 h of culture, transfected cells
were analyzed for expression of BH3-only genes by real-time quan-
titative PCR. Data are shown as fold induction compared with cells
transfected with the empty vector. (B) SUM159 cells were treated with
1 lM adriamycin for 3 h, and the formation of E2F1–DNA binding
complexes was determined by EMSA as in Fig. 3B. Nuclear extracts
were preincubated with the indicated antibodies. (C) SUM159 cells
were transfected with Bik-Luc and treated with 10 lM adriamycin for
16 h. Cell extracts were analyzed for the relative luciferase activity as in
Fig. 3A.
Fig. 5. E2F proteins induce bik by a p53-independent pathway and do
not promote apoptosis. (A) SHSY-5Y cells were transfected with Bik-
Luc and E2F1 or p53, and after 24 h of incubation, cell extracts were
analyzed for the relative luciferase activity. Cells were also transfected
with a luciferase reporter vector containing the mdm2 promoter in the
presence of p53. (B) p53 null and wild type HCT116 cells were
transfected with Bik-Luc and E2Fs. By 24 h of transfection, the
luciferase activity was analyzed as in Fig. 3A. (C) Cells were
transfected with a GFP-containing vector in the presence or in the
absence of E2F1, and the percentage of GFP-positive apoptotic cells
were determined by ﬂow cytometry with phycoerythrin-labeled
annexin V. (D) Wild type HCT116 cells were transfected with E2F1
or E2F2 and apoptosis was analyzed as in (C). Expression of
exogenous proteins in cell extracts were also determined by Western
blotting with anti-HA antibodies. C, untreated cells; All data points
represent the means ± S.D. of three independent experiments.
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and data not shown). Thus, at least in these cell systems, over-
expression of E2F proteins is not suﬃcient to promote apopto-
sis.
4. Discussion
We have shown that adriamycin induces bik in a p53-inde-
pendent manner. By contrast, it has been previously described
that p53 independently induced bik [14]. However, in line with
our results, bik is induced in p53-deﬁcient lymphoma cells fol-
lowing treatment with camptothecin [15]. Consistent with this
apparent discrepancy is that there is marked variation in the
intrinsic ability of cancer cells to activate the p53 apoptotic
pathway in response to chemotherapy [16], which suggests that
other transcriptional mechanisms may contribute to the
expression of bik.
We found that E2Fs transactivate the bik gene. In line with
this, E2Fs have been shown to induce the expression of a num-
ber of BH3-only genes including puma and bim [5]. Moreover,
we described that a partial blockade of bik expression reduced
the levels of chemotherapy-induced apoptosis. However, the
presence of active p53 appeared to be necessary for an eﬃcient
apoptotic response to chemotherapeutic agents, which is in
agreement with the well known participation of this tumour
suppressor in apoptosis [17]. Overexpression of bik has beenpreviously shown to promote apoptosis [18]. By contrast, we
found that although E2Fs eﬃciently upregulated bik, this tran-
scriptional mechanism had no eﬀect on cell survival. Consistent
with our result is the argument that Bik is not a direct initiator
of apoptosis, but sensitizes cells to death stimuli by reducing the
level of free pro-survival Bcl-2-family members [19]. An alter-
native explanation for the lack of killing activity is that bik can-
not neutralize all the pro-survival proteins expressed
substantially in the studied cells. In support of this, recent data
have shown that Noxa BH3, which selectively binds Mcl-1, po-
tently enhances killing by Bik, which preferentially binds Bcl-
xL, reﬂecting complementary BH3 function [20]. Thus, a likely
model is that E2F proteins are activating bik, among other
apoptotic genes, through a p53-independent mechanism, and
this transcriptional pathway may act in conjunction with p53
and its apoptotic target genes for a complete response to che-
motherapeutic agents. Consistently, our knock-down experi-
ments indicate that bik contributes to chemosensitization.
Based on these data, bik seems to participate in a regulatory
network of factors that control apoptosis in response to chemo-
therapy. In line with this, it is generally accepted that multiple
pro-survival proteins must be inactivated to unleash Bax and
Bak, which drive apoptosis [21]. Some BH3-only members bind
and block all the pro-survival proteins, whereas others engage
distinct subsets and exhibit complementary killing. Hence, mul-
tiple BH3-only proteins are most likely activated to mount an
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chemotherapy appears to be cell type dependent.
Together, this study shows a role of E2F proteins in the
transcriptional regulation of bik, and supports that this path-
way can be activated by chemotherapeutic agents, thus con-
tributing to the apoptotic response to chemotherapy. Further
studies will need to deepen the understanding of the physiolog-
ical relevance of this transcriptional pathway in normal and
cancer cells.
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